Wegovy

Novo Nordisk raised its 2026 outlook following strong sales performance from its newly launched Wegovy pill, which exceeded forecasts. This demonstrates the pharmaceutical sector's ability to drive significant stock gains through successful product launches in high-demand therapeutic areas like obesity treatment.

Amazon launched a GLP-1 weight loss program through Amazon Pharmacy, providing access to Novo Nordisk's Wegovy and newer oral GLP-1 medications. This expansion positions Amazon to capture market share in the rapidly growing weight management pharmaceutical sector, potentially affecting traditional pharmacy chains.